The degree of intrinsic and interpatient phenotypic heterogeneity and its role in tumor evolution is poorly understood. Phenotypic drifts can be transmitted via inheritable transcriptional programs. Cell-type specific transcription is maintained through the activation of epigenetically defined regulatory regions including promoters and enhancers. Here we have annotated the epigenome of 47 primary and metastatic estrogen-receptor (ER alpha)-positive breast cancer clinical specimens and inferred phenotypic heterogeneity from the regulatory landscape, identifying key regulatory elements commonly shared across patients. Shared regions contain a unique set of regulatory information including the motif for transcription factor YY1. We identify YY1 as a critical determinant of ER alpha transcriptional activity promoting tumor growth in most luminal patients. YY1 also contributes to the expression of genes mediating resistance to endocrine treatment. Finally, we used H3K27ac levels at active enhancer elements as a surrogate of intra-tumor phenotypic heterogeneity to track the expansion and contraction of phenotypic subpopulations throughout breast cancer progression. By tracking the clonality of SLC9A3R1-positive cells, a bona fide YY1-ER alpha-regulated gene, we show that endocrine therapies select for phenotypic clones under-represented at diagnosis. Collectively, our data show that epigenetic mechanisms significantly contribute to phenotypic heterogeneity and evolution in systemically treated breast cancer patients.

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer / D.K. Patten, G. Corleone, B. Győrffy, Y. Perone, N. Slaven, I. Barozzi, E. Erdős, A. Saiakhova, K. Goddard, A. Vingiani, S. Shousha, L.S. Pongor, D.J. Hadjiminas, G. Schiavon, P. Barry, C. Palmieri, R.C. Coombes, P. Scacheri, G. Pruneri, L. Magnani. - In: NATURE MEDICINE. - ISSN 1078-8956. - 24:9(2018 Sep), pp. 1469-1480. [10.1038/s41591-018-0091-x]

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer

I. Barozzi;A. Vingiani;G. Pruneri
Penultimo
;
2018

Abstract

The degree of intrinsic and interpatient phenotypic heterogeneity and its role in tumor evolution is poorly understood. Phenotypic drifts can be transmitted via inheritable transcriptional programs. Cell-type specific transcription is maintained through the activation of epigenetically defined regulatory regions including promoters and enhancers. Here we have annotated the epigenome of 47 primary and metastatic estrogen-receptor (ER alpha)-positive breast cancer clinical specimens and inferred phenotypic heterogeneity from the regulatory landscape, identifying key regulatory elements commonly shared across patients. Shared regions contain a unique set of regulatory information including the motif for transcription factor YY1. We identify YY1 as a critical determinant of ER alpha transcriptional activity promoting tumor growth in most luminal patients. YY1 also contributes to the expression of genes mediating resistance to endocrine treatment. Finally, we used H3K27ac levels at active enhancer elements as a surrogate of intra-tumor phenotypic heterogeneity to track the expansion and contraction of phenotypic subpopulations throughout breast cancer progression. By tracking the clonality of SLC9A3R1-positive cells, a bona fide YY1-ER alpha-regulated gene, we show that endocrine therapies select for phenotypic clones under-represented at diagnosis. Collectively, our data show that epigenetic mechanisms significantly contribute to phenotypic heterogeneity and evolution in systemically treated breast cancer patients.
Breast Neoplasms; Cell Line, Tumor; Clone Cells; Enhancer Elements, Genetic; Epigenesis, Genetic; Estrogen Receptor alpha; Estrogens; Female; Humans; MCF-7 Cells; Phenotype; Phosphoproteins; Polymorphism, Single Nucleotide; Protein Binding; Risk Factors; Sodium-Hydrogen Exchangers; Transcription, Genetic; YY1 Transcription Factor; Clonal Evolution
Settore MED/08 - Anatomia Patologica
Settore MED/06 - Oncologia Medica
Settore MED/04 - Patologia Generale
set-2018
23-lug-2018
https://hdl.handle.net/2434/939397
Article (author)
File in questo prodotto:
File Dimensione Formato  
s41591-018-0091-x.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 4.35 MB
Formato Adobe PDF
4.35 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/939376
Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 76
social impact